For decades, hydroquinone was the answer when patients came in with melasma, post-inflammatory hyperpigmentation (PIH), or stubborn dark spots. Effective, proven, and well-studied — but increasingly difficult to recommend without caveats.

The EU banned hydroquinone for over-the-counter cosmetic use in 2001. Dermatologists in the US increasingly require cycling protocols (3 months on, 1 month off) to manage long-term risk. And rebound hyperpigmentation — the worsening of dark spots after discontinuation — is a real clinical phenomenon that many patients have experienced firsthand.

Tranexamic acid has emerged as the most studied alternative. This is what the evidence shows, and why a growing number of physicians are making the switch.

Shop CODE3 — $240

How Hydroquinone Works — and Why It Has Problems

Hydroquinone inhibits tyrosinase, the enzyme that converts tyrosine into melanin. It is effective. That is not the dispute.

The concerns are:

• Ochronosis (exogenous): A paradoxical darkening reaction caused by long-term, high-dose hydroquinone use. More commonly reported with concentrations above 4% or with prolonged use, particularly in darker skin types.
• Rebound hyperpigmentation: When hydroquinone is discontinued, melanocytes often upregulate — returning to baseline or worsening. Patients who stop need a maintenance plan.
• Prescription requirements: In the US, concentrations above 2% require a prescription. In the EU, it is banned for cosmetic OTC use entirely.
• Cycling protocols: Most physicians recommend 3 months on, 1 month off — limiting its practicality as a long-term maintenance ingredient.

None of this makes hydroquinone dangerous at standard doses under physician supervision. But for patients managing a chronic condition like melasma, the cycling requirements and rebound risk make it a treatment rather than a solution.

How Tranexamic Acid Works Differently

Tranexamic acid does not inhibit tyrosinase. It works through an entirely different mechanism: blocking plasmin, a serine protease that activates melanocytes through keratinocyte signaling.

This distinction matters for several reasons:

1. No tyrosinase inhibition means no rebound tied to that mechanism
2. No or reduced ochronosis risk — the reaction that causes paradoxical darkening is specific to hydroquinone and similar tyrosinase inhibitors
3. No cycling required — TXA is safe for long-term continuous use
4. Available OTC — topical TXA does not require a prescription at any concentration

The evidence base is substantial:

• An expert consensus review (PMID: 37264783) established TXA protocols for melasma, with oral administration showing up to 89% reported success rate — supporting the broader evidence for TXA's melanogenesis-inhibiting mechanism
• Multiple split-face trials and controlled studies confirm topical TXA's efficacy for melasma and PIH
• Head-to-head comparisons with hydroquinone show equivalent MASI (Melasma Area and Severity Index) reduction with superior tolerability

Topical TXA delivers these results locally, without systemic considerations.

Concentration Matters

Not all TXA serums are equivalent. Studies demonstrating efficacy generally use concentrations between 3% and 10%. Many commercial TXA products use 2% or less — concentrations that have not been validated in the published literature for active treatment.

CODE3 uses 10% tranexamic acid — one of the highest concentrations in a non-prescription topical. That choice was deliberate: maximum mechanism engagement within the safety profile supported by clinical data.

Why TXA Alone Is Not Enough

The reason melasma returns in many patients — even on effective treatment — is that pigmentation runs on more than one pathway.

Melanocytes can be activated by:

1. Plasmin signaling — the pathway TXA blocks
2. Inflammatory cytokines — triggered by UV, acne, friction, or irritation
3. Reactive oxygen species (ROS) — generated by UV and environmental stressors

A product that only addresses the plasmin pathway leaves two doors open. If your skin is inflamed or experiencing oxidative stress, melanocytes will continue to activate regardless of TXA.

This is why CODE3 pairs tranexamic acid with:

• Bakuchiol — a retinol-alternative that reduces inflammation without retinol's irritation or photosensitivity concerns. Clinically validated in a 12-week randomized trial (British Journal of Dermatology, 2019) against retinol for pigmentation and photoaging: comparable outcomes, significantly fewer adverse events.
• Quercetin — a flavonoid antioxidant that scavenges ROS and blocks the oxidative stress pathway to melanogenesis. A 2024 systematic review (PMID: 39738831) confirmed quercetin's antioxidant activity and its role in supporting skin repair through fibroblast stimulation.

Three ingredients. Three pathways. Hydroquinone addresses one mechanism and stops there.

Making the Switch

If you are currently using a hydroquinone product and want to transition:

• Consult your doctor. Abrupt discontinuation of hydroquinone without a replacement can trigger rebound. Consult your prescribing physician for how to introduce TXA into your routine.
• Give TXA time. Expect 4–8 weeks before visible improvement. Melanocyte activity changes more slowly than the surface effects of some actives.
• Continue mineral SPF. UV is the primary ongoing trigger for all three pigmentation pathways. Sunscreen is not optional.
• Address all three pathways. Single-mechanism TXA serums are a meaningful step up from hydroquinone but still leave the inflammation and oxidative stress pathways unmanaged.

Shop CODE3 — $240

---

References:
Oral Tranexamic Acid for Melasma: Evidence and Experience-Based Consensus. PMID: 37264783 (2023)
Topical tranexamic acid as a promising treatment for melasma. PMC 4235096
Bakuchiol vs. retinol: prospective, randomized, double-blind study. British Journal of Dermatology, 2019;180(2):289-296
Quercetin as a therapeutic agent for skin: systematic review and meta-analysis. PMID: 39738831 (2024)

---

Alón Labs makes clinically-driven topicals for skin tone and long-term pigment correction. CODE3 is a patent-pending formula of Tranexamic Acid + Bakuchiol + Quercetin developed by a board-certified plastic surgeon.